PDCD1 and breast cancer: Increased interaction of inactivated GSK3β with PDL1 has been found in basal-like breast cancer (Li et al., 2016), and GSK3α/β inactivation blocks PD1 expression in CD8+ cytotoxic T lymphocytes (CTLs) and enhances immunity through PD1 downregulation (Taylor et al., 2016).